SecBot SecBot
6-K ·Filed Jul 2, 2026

ABVX

Abivax S.A.
BEARISH
Impact 6/10
Horizondays Processed4mo ago SEC0001193125-26-294514
Notable filing: 6-K
Actionable Insight ▼ Bearish

The $800M capital raise provides Abivax with a substantial cash runway, but the dilutive offering at a ~30% premium to the prior close will likely pressure the stock in the near term as the market absorbs the new shares. Monitor the stock for post-offering stabilization and watch for any pipeline updates that could justify the dilution. The 60-day lock-up on insiders provides some near-term support, but the large overhang from the offering will likely cap upside in the near term.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$144.65
T+0 close · Jul 2, 2026 · via day close
Latest settled
−33.05%
T+60 · $96.85
Vs SPY
−36.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $144.65entry
  2. T+1 · 4mo ago −0.46%α −1.33% · $143.99
  3. T+5 · 4mo ago −2.70%α −3.63% · $140.74
  4. T+20 · 4mo ago −14.05%α −13.63% · $124.33
  5. T+60 · 7w ago −33.05%α −36.61% · $96.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abivax SA filed a 6-K on July 2, 2026, disclosing the entry into an underwriting agreement for a public offering of 6,400,000 ADSs at $125.00 per ADS, with an option for underwriters to purchase up to an additional 960,000 ADSs. Gross proceeds are $800 million ($762 million net before expenses), with net proceeds expected to be approximately $759.8 million. The offering, which was upsized from an initial $600 million preliminary prospectus, closed at a $125.00 price versus a $96.15 prior close, representing a ~30% premium to the prior day's close, but the offering is dilutive to existing shareholders.

Key Facts

  • Abivax entered into an underwriting agreement for a public offering of 6,400,000 ADSs at $125.00 per ADS, with an option for underwriters to purchase up to an additional 960,000 ADSs.
  • Gross proceeds from the offering are $800 million; net proceeds to the Company are expected to be approximately $759.8 million.
  • The offering price of $125.00 per ADS represents a ~30% premium to the prior day's close of $96.15 per ADS.
  • The offering was upsized from an initial $600 million preliminary prospectus to $800 million.
  • The offering is expected to close on July 6, 2026, subject to customary closing conditions.
  • The offering was conducted without preferential subscription rights for existing shareholders, resulting in dilution.

Financial Impact

Gross proceeds of $800 million from 6,400,000 ADSs at $125.00 per ADS; net proceeds of approximately $759.8 million after underwriting discounts and estimated expenses. The offering represents ~7.6% dilution to existing shareholders before the greenshoe option.

dilutioncashshare count

Risk Factors

  • Dilution from the 6,400,000 new ADSs (up to 7,360,000 with greenshoe) will pressure the stock price near-term.
  • The offering was conducted without preferential subscription rights, meaning existing shareholders were diluted without the opportunity to maintain their proportional ownership.
  • The offering is large relative to market cap (~7.6% dilution before greenshoe) and may take time for the market to absorb.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-294514
Document: d108401dex51.htm0001193125-26-294514
Document: d108401d6k.htm0001193125-26-294514
Document: 0001193125-26-294514-index-headers.html0001193125-26-294514
Document: 0001193125-26-294514-index.html0001193125-26-294514
Document: 0001193125-26-294514.txt0001193125-26-294514

Track record

10 reports on ABVX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $87.58 +5.01% settles Nov 24
  2. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $87.58 +1.14% ▼ −0.99% +1.71% vs SPY
  3. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $87.58 −32.63% ▼ −6.58% −7.79% vs SPY
  4. Jul 2, 202619w ago 6-K Bearish 6/10 Viewing Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  5. Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  6. Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $87.58 +33.93% ▼ −7.25% −6.99% vs SPY
  7. Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  8. Jun 29, 202620w ago Press Release Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  9. May 22, 202625w ago Press Release Neutral 5/10 Entry $126.41 to $129.69 Now $87.58 −30.72% ▲ +2.59% +1.51% vs SPY
  10. Mar 23, 202634w ago Press Release Mixed 6/10 Entry $110.17 to $111.35 Now $87.58 −20.50% ▲ +1.07% +1.49% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (12h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026